Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (295)	1/17/1999 1:52:00 PM
From: Mike McFarland	Respond to of 656

I caught that show the other day. The CEO mainly just went on about Enbrel prospects, implied that there may be a pop with sales initially for all the folks who test drive the product, but was also very optimistic that a lot of folks with RA would make the switch. He also went on about the postcards etc they have received from grateful patients, and of course talked about juvenile arthritis. Mainly a feel good presentation...he even had the confidence to suggest that Mitzman would have him on again next year...that would be three appearances each year right in a row, which is not very likely. I am 90% sure that it was he, and not the ceo of Pathogenesis, who stated that they were looking at aquisitions. Barry Mitzman pressed him on this and he said something like well this would not be happening until 2000, to which Mitzman said that's only a year away, blah blah blah. No science, not even enough science was in the discussion for a biotech newbie like myself. So, if anybody wants to read about TNF (at least the acronym "TNF" was quickly blurted out...) here is the Enbrel prescription url enbrelinfo.com